Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMG 193 combination master protocol in MTAP-deleted advanced gastrointestinal, biliary tract, or pancreatic cancers
NL-OMON59349Phase 1Completed
- Sponsor
- Amgen
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1 trial of anvumetostat in gastrointestinal cancer, biliary cancer and pancreatic cancer (PC), sponsored by Amgen. Started Oct 2024; status: completed.
02
Drugs
anvumetostat
03
Conditions
gastrointestinal cancerbiliary cancerpancreatic cancer (PC)
Beyond the preview
Go deeper on NL-OMON59349.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59349.